Union Commerce and Industry Minister Piyush Goyal on Tuesday said the Centre remains committed to building a globally competitive and innovation-driven pharmaceutical sector while ensuring affordable healthcare for all.
In a post on X, Goyal said he held a “productive interaction” with a delegation from the Indian Pharmaceutical Alliance (IPA), led by its President, Dr Sharvil Patel.
The meeting focused on strengthening India’s pharmaceutical innovation ecosystem by attracting greater investments in research and development (R&D), clinical research, and advanced therapeutics. The discussions also explored ways to deepen collaboration between the government and the industry to accelerate innovation and enhance the sector’s global competitiveness.
Reaffirming the Modi government’s commitment to the sector, Goyal said the Centre is working to create an enabling environment that promotes innovation while ensuring access to affordable medicines.
India’s pharmaceutical industry, one of the largest in the world, plays a critical role in supplying affordable generic medicines to global markets. The government has rolled out several initiatives in recent years to boost domestic manufacturing, research, and innovation in the sector.
The sector has also witnessed strong deal activity. According to a recent report, India’s pharmaceutical and healthcare industry recorded 65 deals worth $13.9 billion in the second quarter of 2026.
Even after excluding an $11.8 billion overseas acquisition—the largest-ever international purchase by an Indian pharmaceutical company—overall deal values rose 12 per cent compared with the previous quarter.
Mergers and acquisitions accounted for 35 deals worth $13.2 billion, with transaction volumes increasing 17 per cent quarter-on-quarter and deal values reaching an all-time high. Outbound transactions contributed 96 per cent of the total M&A value. (IANS)
